Clene Inc. Files 8-K with SEC
Ticker: CLNN · Form: 8-K · Filed: Sep 16, 2024 · CIK: 1822791
| Field | Detail |
|---|---|
| Company | Clene Inc. (CLNN) |
| Form Type | 8-K |
| Filed Date | Sep 16, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001, $230.00 |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, corporate-update, pharmaceuticals
TL;DR
Clene Inc. filed an 8-K on Sept 16, 2024. Standard reporting.
AI Summary
Clene Inc. filed an 8-K on September 16, 2024, reporting other events and financial statements. The company, previously known as Chelsea Worldwide Inc., is incorporated in Delaware and operates in the pharmaceutical preparations industry. Its principal executive offices are located in Salt Lake City, Utah.
Why It Matters
This filing provides an update on Clene Inc.'s corporate activities and financial reporting to the SEC, which is important for investors and stakeholders to monitor the company's status.
Risk Assessment
Risk Level: low — This is a routine SEC filing (8-K) reporting standard corporate information and events, not indicating any immediate financial distress or significant operational change.
Key Numbers
- 85-2828339 — IRS Employer Identification No. (Company tax identification)
- 001-39834 — SEC File Number (Company SEC filing identifier)
Key Players & Entities
- Clene Inc. (company) — Registrant
- Chelsea Worldwide Inc. (company) — Former company name
- September 16, 2024 (date) — Date of report
- Salt Lake City, Utah (location) — Principal executive offices
- 001-39834 (other) — SEC File Number
FAQ
What is the primary purpose of this 8-K filing for Clene Inc.?
The 8-K filing serves to report 'Other Events' and 'Financial Statements and Exhibits' as of September 16, 2024.
When was Clene Inc. previously known by another name?
Clene Inc. was formerly known as Chelsea Worldwide Inc., with a date of name change on August 27, 2020.
Where are Clene Inc.'s principal executive offices located?
Clene Inc.'s principal executive offices are located at 6550 South Millrock Drive, Suite G50, Salt Lake City, Utah 84121.
What is Clene Inc.'s Standard Industrial Classification (SIC) code?
Clene Inc.'s SIC code is 2834, which corresponds to Pharmaceutical Preparations.
What is the SEC file number for Clene Inc.?
The SEC file number for Clene Inc. is 001-39834.
Filing Stats: 488 words · 2 min read · ~2 pages · Grade level 10.6 · Accepted 2024-09-16 08:32:54
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value CLNN The Nasdaq Capital M
- $230.00 — rtieth of one share of Common Stock for $230.00 per share CLNNW The Nasdaq Capital
Filing Documents
- clnn20240912_8k.htm (8-K) — 28KB
- ex_723588.htm (EX-99.1) — 12KB
- 0001437749-24-029205.txt ( ) — 190KB
- clnn-20240916.xsd (EX-101.SCH) — 4KB
- clnn-20240916_def.xml (EX-101.DEF) — 13KB
- clnn-20240916_lab.xml (EX-101.LAB) — 17KB
- clnn-20240916_pre.xml (EX-101.PRE) — 13KB
- clnn20240912_8k_htm.xml (XML) — 5KB
01 Other Events
Item 8.01 Other Events. On September 16, 2024, Clene Inc. (the "Company") issued a press release announcing the Company was granted an in-person meeting with U.S. Food and Drug Administration ("FDA") senior leadership to discuss CNM-Au8 biomarker and related clinical and survival data. A copy of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K (the "Current Report") and is incorporated herein by reference.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit Number Exhibit Description 99.1 Press release, dated September 16, 2024, announcing Clene granted in-person meeting with FDA senior leadership to discuss CNM-Au8 biomarker and related clinical and survival data. 104 Cover Page Interactive Data File (formatted as Inline XBRL). 1
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized. CLENE INC. Date: September 16, 2024 By: /s/ Robert Etherington Robert Etherington President and Chief Executive Officer 2